Jun 24, 2025, 20:58
Saving Lives with Guidelines? ISTH 2025: Prophylactic Anticoagulation Reduces VTE by 60% and Mortality by 56%
Marc Carrier posted on X:
”Implementation matters! A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. ISTH 2025, VTE Prevention”
ISTH 2025 is full of surprises we didn’t know we needed. Turns out, guidelines bring common sense to life—eventually!
Marc Carrier, MD, MSc, FRCPC, urges us to adopt the Vermont Model for prophylactic anticoagulation, in pursuit of grand reductions in VTE and death among high-risk cancer patients.
To stay updated on the world of thrombosis, be sure to subscribe to Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch